Theriva Biologics TOVX
NYSE TOVX
$0.24 +0.01 (+4.35%)
At close: Oct 2, 2026 · 4:00 PM EDT

Theriva Biologics (TOVX) Price to Sales (2011)

Updated

Theriva Biologics' Price to Sales came in at 577.87 for Q3 2011, up 99.5% from the prior quarter.

Analysis

Theriva Biologics (TOVX) Price to Sales (2011) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Theriva Biologics 11.01 Mn 11.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2011 577.87
Jun 30, 2011 289.65
API Access

Theriva Biologics Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=TOVX&period=max&api_key=YOUR_API_KEY